1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Abeille Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Abeille Pharmaceuticals, Inc. - Product Pipeline Review - 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 19 pages

Abeille Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Abeille Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the Abeille Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Abeille Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Abeille Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Abeille Pharmaceuticals, Inc. - Brief Abeille Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Abeille Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Abeille Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Abeille Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Abeille Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Abeille Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Abeille Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Abeille Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Abeille Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

Abeille Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Abeille Pharmaceuticals, Inc. Snapshot 4
Abeille Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
Abeille Pharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Abeille Pharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Out-Licensed Products 9
Out-Licensed Products/Combination Treatment Modalities 10
Abeille Pharmaceuticals, Inc. - Pipeline Products Glance 11
Abeille Pharmaceuticals, Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Abeille Pharmaceuticals, Inc. - Drug Profiles 12
AB-1003 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
AB-1101 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
AB-3001 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Abeille Pharmaceuticals, Inc. - Pipeline Analysis 15
Abeille Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 15
Abeille Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 16
Abeille Pharmaceuticals, Inc. - Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
Coverage 18
Secondary Research 18
Primary Research 18
Expert Panel Validation 18
Contact Us 19
Disclaimer 19



List of Tables

Abeille Pharmaceuticals, Inc., Key Information 4
Abeille Pharmaceuticals, Inc., Key Facts 4
Abeille Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Abeille Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Abeille Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Abeille Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2013 9
Abeille Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2013 10
Abeille Pharmaceuticals, Inc. - Preclinical, 2013 11
Abeille Pharmaceuticals, Inc. - Pipeline by Therapeutic Class, 2013 15
Abeille Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2013 16



List of Figures

Abeille Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2013 6
Abeille Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2013 9
Abeille Pharmaceuticals, Inc. - Pipeline by Top 10 Therapeutic Class, 2013 15
Abeille Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2013 16



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016 ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.